Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Treximet Articles

Pozen out-licenses migraine drug candidate to Desitin for EU

9 May 2012

Pozen sells future royalty rights to Treximet for $75 million

28 November 2011

Pozen cuts loss 53%, attracts Zacks interest

6 May 2009

Pozen shares drop 28% on Treximet challenge

27 October 2008

$20M GSK milestone for Pozen

5 May 2008

GSK's Treximet receives FDA approval

21 April 2008

Showing 1-6 of 6 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • SciClone gains China rights to Zensun's Neucardin
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • SciClone gains China rights to Zensun's Neucardin

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS